A phase 2 trial shows promising results for pembrolizumab combined with cisplatin and radiation in treating unresectable ...

A pre-surgical combination therapy including pembrolizumab plus dabrafenib and trametinib (DTP) significantly improved ...

First-line treatment with sacituzumab govitecan plus pembrolizumab showed significant improvement in PFS vs. chemotherapy ...

Sacituzumab govitecan plus pembrolizumab improves outcomes vs chemotherapy plus pembrolizumab in patients with previously untreated, PD-L1+ TNBC.

"These long-term results continue to support [pembrolizumab's] use as a standard of care for patients at increased risk of ...

Almost one in five patients with advanced melanoma survived for five years after receiving lifileucel, a trial has found.

New phase 3 data show that sacituzumab govitecan plus pembrolizumab delays cancer progression in PD-L1-positive metastatic ...

In patients with an aggressive form of breast cancer, treatment with the antibody-drug conjugate sacituzumab govitecan plus ...

The results of this phase III KEYNOTE-991 study do not support the addition of pembrolizumab to enzalutamide and ADT for the treatment of mHSPC,” researchers wrote.

A grandad diagnosed with stage 4 lung cancer–one of the deadliest—has become disease-free after being treated with an ...

We know from the phase 2 TROPHY-U-01 trial that sacituzumab govitecan is an active drug, with an objective response rate of ...

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for ...